Abbott Laboratories $ABT Shares Sold by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 1.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 42,169 shares of the healthcare product maker’s stock after selling 517 shares during the period. Abbott Laboratories makes up 1.8% of Brown Miller Wealth Management LLC’s portfolio, making the stock its 6th biggest position. Brown Miller Wealth Management LLC’s holdings in Abbott Laboratories were worth $5,735,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the first quarter valued at $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the first quarter valued at about $30,000. JCIC Asset Management Inc. acquired a new stake in Abbott Laboratories in the first quarter worth about $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories during the 1st quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ABT shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research note on Saturday, September 27th. Wells Fargo & Company cut their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Mizuho lifted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Evercore ISI upped their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $145.39.

Abbott Laboratories Stock Performance

ABT opened at $134.49 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market cap of $234.07 billion, a PE ratio of 16.85, a P/E/G ratio of 2.55 and a beta of 0.69. The business has a fifty day simple moving average of $131.94 and a 200-day simple moving average of $131.36. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.